Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05954481
Other study ID # 69HCL22_0487
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 3, 2023
Est. completion date August 2024

Study information

Verified date August 2023
Source Hospices Civils de Lyon
Contact Cyrille BERGEROT, Dr
Phone 04 72 11 93 61
Email cyrille.bergerot@chu-lyon.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The hepatic involvement of HHT (Hereditary Haemorrhagic Telangiectasia) disease is characterised by the formation of arterio-sus-hepatic shunts which lead to dilatation of the hepatic artery and may result in high output heart failure. This evolves silently for long-standing period from left ventricular cavities dilatation to advanced heart failure with post-capillary pulmonary hypertension (PH) (more rarely pre-capillary), and its evolution is poorly understood. The specific treatment options for HHT disease are either the use of anti-angiogenic therapy (bevacizumab) or liver transplantation. As rest echocardiography can only detect advanced cases or heart failure with rest PH, the investigators speculate that exercise echocardiography can provide additional information in patients without rest PH. The hypothesis is that an exaggerated pulmonary pressure increase during exercise may precede the occurrence of rest PH in the course of the disease. It could identify patients with substantial heart failure at an earlier stage and may facilitate the access to liver transplantation. These parameters have never been studied in this context and it seems interesting to evaluate them in this pilot study. The investigators hypothesise that HHT (Hereditary Haemorrhagic Telangiectasia) patients with hepatic involvement and cardiac high output will have significantly greater and/or earlier elevation of exercise pulmonary arterial pressures than those with normal cardiac output.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - HHT patient > 18 yo - Hepatic involvement (hepatic artery diameter > 6mm) - Patient having received the information and signed the informed consent form - Patient affiliated to a social security scheme or beneficiaries of a similar scheme Exclusion Criteria: - Haemoglobin < 90 g/L - Active Infection - Atrial Fibrillation permanent or persistent - Known cardiopathy - Pregnant or breastfeeding woman (by questioning) - Adult subject to a legal protection measure (guardianship) - Participation in another clinical trial that may interfere with the proposed trial (investigator judgment) - Patient physically unable to pedal - Patient with Pulmonary arteriovenous malformations awaiting embolization - Patient treated with beta-blockers Secondary Exclusion Criteria verified on rest ultrasound - PAH (Pulmonary Arterial Hypertension) at rest (Vmax > 2.8 m/sec) - Inability to obtain a stream of IT at rest - Patient with atrial fibrillation (AF)

Study Design


Related Conditions & MeSH terms

  • Hereditary Hemorrhagic Telangiectasia
  • Telangiectasia, Hereditary Hemorrhagic
  • Telangiectasis

Intervention

Other:
Stress echocardiography
After a rest trans thoracic echocardiography (usual follow-up), eligible patients will have a stress ultrasound echocardiography on a dedicated cycle ergometer

Locations

Country Name City State
France Service Explorations fonctionnelles cardiovasculaires - Hôpital Louis Pradel Bron
France Service génétique - Hôpital Femme Mère Enfant Bron

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of exercise pulmonary artery systolic pressure in patients with HHT and liver involvement. The systolic pulmonary artery pressure (PAPS) during exercise will be compared between the two groups of patients. PAPS will be estimated by the maximum velocity (Vmax) of tricuspid insufficiency flow at peak exercise on cardiac ultrasound. Day 1
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02874326 - Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber Phase 2
Completed NCT00389935 - Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding Phase 2
Active, not recruiting NCT04646356 - Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT) Phase 2
Completed NCT04139018 - Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia Phase 2
Completed NCT03691142 - Evaluation of Obstetrical and Neonatal Complications in Hereditary Haemorrhagic Telangiectasia (HHT)
Recruiting NCT04404881 - Bevacizumab In Hereditary Hemorrhagic Telangiectasia Phase 2
Completed NCT02977637 - MRA With Feraheme in HHT Phase 1
Completed NCT01485224 - Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia Phase 2
Recruiting NCT06259292 - Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Active, not recruiting NCT04150822 - Hereditary Hemorrhagic Telangiectasia (HHT) Research Outcomes Registry
Recruiting NCT03850964 - Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) Phase 2/Phase 3
Completed NCT05752253 - Counseling Intervention in Hereditary Hemorrhagic Telangiectasia in the COVID Era. N/A
Not yet recruiting NCT02458703 - Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction N/A
Completed NCT01752049 - Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept Phase 1/Phase 2
Completed NCT00004649 - Study of the Natural History and Genotype-Phenotype Correlations of Hereditary Hemorrhagic Telangiectasia Patients N/A
Active, not recruiting NCT04874558 - Ultra-low-dose Chest CT for HHT
Completed NCT01031992 - Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Phase 3
Recruiting NCT05269849 - Sirolimus for Nosebleeds in HHT Phase 2
Completed NCT03572556 - Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)
Completed NCT04113187 - Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients Phase 3